Julia Barczuk

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Advanced Non Small Cell Lung Cancer

Estrogen Receptor

Endoplasmic Reticulum

Signaling Pathway

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Wioletta Rozpedek-Kaminska, Grzegorz Galita, Natalia Siwecka, Zuzanna Granek, Julia Barczuk, Kamil Saramowicz, Ireneusz Majsterek
NCI 159456 PERK Inhibitor as a Targeted Therapy for Lung Cancer: An In Vitro Study. Biomedicines 12 (4) (2024)
Wioletta Rozpedek-Kaminska, Grzegorz Galita, Kamil Saramowicz, Zuzanna Granek, Julia Barczuk, Natalia Siwecka, Dariusz Pytel, Ireneusz Majsterek
Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes. International journal of molecular sciences 25 (2) (2024)
Wioletta Rozpedek-Kaminska, Grzegorz Galita, Natalia Siwecka, Zuzanna Granek, Julia Barczuk, Kamil Saramowicz, Ireneusz Majsterek
NCI 159456 PERK Inhibitor as a Targeted Therapy for Lung Cancer: An In Vitro Study. Biomedicines 12 (4) (2024)
Wioletta Rozpedek-Kaminska, Grzegorz Galita, Kamil Saramowicz, Zuzanna Granek, Julia Barczuk, Natalia Siwecka, Dariusz Pytel, Ireneusz Majsterek
Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes. International journal of molecular sciences 25 (2) (2024)
Wioletta Rozpedek-Kaminska, Grzegorz Galita, Kamil Saramowicz, Zuzanna Granek, Julia Barczuk, Natalia Siwecka, Dariusz Pytel, Ireneusz Majsterek
Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes. International journal of molecular sciences 25 (2) (2024)
Wojciech Wiese, Julia Barczuk, Olga Racinska, Natalia Siwecka, Wioletta Rozpedek-Kaminska, Artur Slupianek, Radoslaw Sierpinski, Ireneusz Majsterek
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities. Cancers 15 (21) (2023)